联络详情

S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase(HDAC) Inhibitor SB939

S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase (HDAC) Inhibitor SB939 for the Treatment of Recurrent or Metastatic Prostate Cancer (HRPC)

时事通讯

第一时间了解EDBI的最新动态和行业资讯。

提交邮件地址
  • en
  • cn

    • Chinese

    • English
    • Chinese

    © 2021- edbi . 版权所有。